TY - JOUR
TI - Preliminary data of a quantitative point of care test for SARS-CoV-2 antibodies from greece
AU - FRAGKOU, P.C.
AU - PAPAEVANGELOU, V.
AU - ANTONIADOU, A.
AU - KAVVATHA, D.
AU - PLOUSSI, A.
AU - PANTAZIS, N.
AU - SIRMPILANTZE, T.
AU - PSARRAKIS, C.
AU - POURNARAS, S.A.
AU - TSIODRAS, S.
AU - KELEKIS, A.
JO - In vivo (Athens, Greece)
PY - 2020
VL - 34
TODO - 5
SP - 3039-3045
PB - International Institute of Anticancer Research
SN - null
TODO - 10.21873/invivo.12138
TODO - immunoglobulin G;  immunoglobulin M;  SARS-CoV-2 antibody;  virus RNA;  immunoglobulin G;  virus antibody, aged;  Article;  clinical article;  controlled study;  coronavirus disease 2019;  diagnostic test accuracy study;  disease severity;  female;  fluorescence;  follow up;  Greece;  human;  immunoassay;  male;  observational study;  point of care testing;  preliminary data;  prospective study;  quantitative diagnosis;  real time reverse transcription polymerase chain reaction;  RNA extraction;  sensitivity and specificity;  Severe acute respiratory syndrome coronavirus 2;  Betacoronavirus;  blood;  Coronavirus infection;  isolation and purification;  middle aged;  pandemic;  pathogenicity;  point of care system;  virology;  virus pneumonia, Aged;  Antibodies, Viral;  Betacoronavirus;  Coronavirus Infections;  Greece;  Humans;  Immunoglobulin G;  Male;  Middle Aged;  Pandemics;  Pneumonia, Viral;  Point-of-Care Systems;  Sensitivity and Specificity
TODO - Background: Antibody testing is necessary to identify immune individuals in the post-initial wave of the COVID-19 pandemic. Patients and Methods: We prospectively evaluated the performance of a quantitative point-of-care test (POCT) for SARS-CoV-2 antibodies. The patient group (PG) comprised of hospitalized confirmed COVID-19 cases. Asymptomatic healthcare volunteers with negative rRT-PCR were included in the control group (CG). Measurement of IgM and IgG was obtained by dry fluorescence immunoassay. Results: Twenty-six PG (65.9±15.4 years old, male 57.7%) and 18 CG (45.6±10.1 years old, male 33.3%) were included. By manufacturer's cut-off (≥0.04 mIU/ml), sensitivity and specificity were 73.08% and 88.89% for IgM and 88.46% and 33.33% for IgG, respectively. Estimated areas under the ROC curve were 0.907 and 0.848 for IgM and IgG, respectively. Results were improved using a cut-off of IgM ≥0.05 mIU/ml and IgG ≥0.10 mIU/ml. Conclusion: Using stringent cut-off values, SARS-CoV-2 antibody POCT detects immune people and can be used during socioeconomic normalization of communities. © 2020 International Institute of Anticancer Research. All rights reserved.
ER -